000063334 001__ 63334 000063334 005__ 20190709135522.0 000063334 0247_ $$2doi$$a10.18632/oncotarget.21984 000063334 0248_ $$2sideral$$a102081 000063334 037__ $$aART-2017-102081 000063334 041__ $$aeng 000063334 100__ $$0(orcid)0000-0003-0178-4567$$aBorque-Fernando, Ángel$$uUniversidad de Zaragoza 000063334 245__ $$aThe management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry 000063334 260__ $$c2017 000063334 5060_ $$aAccess copy available to the general public$$fUnrestricted 000063334 5203_ $$aThe follow up of patients on active surveillance requires to repeat prostate biopsies. Predictive models that identify patients at low risk of progression or reclassification are essential to reduce the number of unnecessary biopsies. The aim of this study is to validate the Prostate Active Surveillance Study risk calculator (PASS-RC) in the multicentric Spanish Urological Association Registry of patients on active surveillance (AS), from common clinical practice. Results: We find significant differences in age, PSA and clinical stage between our validation cohort and the PASS-RC generation cohort (p < .0001), with a reclassification rate of 10–22% on the follow-up Bx, no cancer was found in 43% of the first follow-up Bx. The calibration curve shows underestimation of real appearance of reclassification. The AUC is 0.65 (C.I.95%: 0.60–0.71). PDF and CUC do not suggest a specific cut-off point of clinical use. Methods: We select 498 patients on AS with a minimum of one follow-up biopsy (Bx) from the 1,024 males registered by 36 Spanish centers recruiting patients on the Spanish Urological Association Registry on AS. PASS-RC external validation is carried by means of calibration curve and area under de ROC-curve (AUC), identifying cut-offs of clinical utility by probability density functions (PDF) and clinical utility curves (CUC). Conclusions: In our first external validation of the PASS-RC we have obtained a moderate discrimination ability, although we cannot recommend cut-off points of clinical use. We suggest the exploration of new biomarkers and/or morpho-functional parameters from multiparametric magnetic resonance image, to improve those necessary tools on AS. 000063334 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000063334 592__ $$a1.942$$b2017 000063334 593__ $$aOncology$$c2017$$dQ1 000063334 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000063334 700__ $$aRubio-Briones, José 000063334 700__ $$0(orcid)0000-0002-3007-302X$$aEsteban, Luis, M. 000063334 700__ $$aCollado-Serra, Argimiro 000063334 700__ $$aPallás-Costa, Yoni 000063334 700__ $$aLópez-González, Pedro, Á. 000063334 700__ $$aHuguet-Pérez, Jorge 000063334 700__ $$aSanz-Vélez, José, I. 000063334 700__ $$aGil-Fabra, Jesús, M. 000063334 700__ $$aGómez-Gómez, Enrique 000063334 700__ $$aQuicios-Dorado, Cristina 000063334 700__ $$aFumadó, Lluis 000063334 700__ $$aMartínez-Breijo, Sara 000063334 700__ $$aSoto-Villalba, Juan 000063334 700__ $$aon behalf of the PIEM Active Surveillance Study Group, 000063334 7102_ $$11004$$2817$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Urología 000063334 773__ $$g8, 65 (2017), 108451-108462$$pONCOTARGET$$tOncotarget$$x1949-2553 000063334 8564_ $$s1665250$$uhttps://zaguan.unizar.es/record/63334/files/texto_completo.pdf$$yVersión publicada 000063334 8564_ $$s118054$$uhttps://zaguan.unizar.es/record/63334/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000063334 909CO $$ooai:zaguan.unizar.es:63334$$particulos$$pdriver 000063334 951__ $$a2019-07-09-11:57:51 000063334 980__ $$aARTICLE